Cardiovascular-kidney-metabolic health reflects the interplay among metabolic risk factors,
chronic kidney disease, and the cardiovascular system and has profound impacts on …

A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors
such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led …

Heart failure (HF) is a clinical syndrome characterized by the presence of dyspnea or limited
exertion due to impaired cardiac ventricular filling and/or blood ejection. Because of its high …

Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide.
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …

Heart failure remains a leading cause of morbidity and mortality worldwide. Current
treatment for patients with heart failure include drugs targeting G protein‐coupled receptors …

This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …

目的: 探讨心外膜脂肪组织(EAT) 厚度与射血分数保留性心力衰竭(HFpEF) 发生风险的相关性.
方法: 选取2019 年8 月—2020 年8 月于郑州大学第一附属医院住院治疗 …

Heart failure (HF) is the cause of impaired exercise capacity due to insufficient peripheral
blood flow. The development of natriuretic peptide (NP) through inhibition of the neprilysin …

Morbid obesity remains most common cause of high output failure. The prevalence of the
obesity is growing when two-thirds of American adults already are overweight or obese …

This review aimed to summarize the adverse events (AEs) reported during the use of
sacubitril/valsartan versus angiotensin converting enzyme inhibitors (ACEI)/angiotensin II …